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Abstract. SLC5A8 and SLC5A12 are sodium-coupled monocarboxylate transporters (SMCTs), the
former being a high-afﬁnity type and the latter a low-afﬁnity type. Both transport a variety of
monocarboxylates in a Na
+-coupled manner. They are expressed in the gastrointestinal tract, kidney,
thyroid, brain, and retina. SLC5A8 is localized to the apical membrane of epithelial cells lining the
intestinal tract and proximal tubule. In the brain and retina, its expression is restricted to neurons and the
retinal pigment epithelium. The physiologic functions of SLC5A8 include absorption of short-chain fatty
acids in the colon and small intestine, reabsorption of lactate and pyruvate in the kidney, and cellular
uptake of lactate and ketone bodies in neurons. It also transports the B-complex vitamin nicotinate.
SLC5A12 is also localized to the apical membrane of epithelial cells lining the intestinal tract and
proximal tubule. In the brain and retina, its expression is restricted to astrocytes and Müller cells.
SLC5A8 also functions as a tumor suppressor; its expression is silenced in tumors of colon, thyroid,
stomach, kidney, and brain. The tumor-suppressive function is related to its ability to mediate
concentrative uptake of butyrate, propionate, and pyruvate, all of which are inhibitors of histone
deacetylases. SLC5A8 can also transport a variety of pharmacologically relevant monocarboxylates,
including salicylates, benzoate, and g-hydroxybutyrate. Non-steroidal anti-inﬂammatory drugs such as
ibuprofen, ketoprofen, and fenoprofen, also interact with SLC5A8. These drugs are not transportable
substrates for SLC5A8, but instead function as blockers of the transporter. Relatively less is known on
the role of SLC5A12 in drug transport.
KEYWORDS: gamma-hydroxybutyrate; kidney/intestine; monocarboxylate drugs; SLC5A8/SLC5A12;
tumor suppressor.
INTRODUCTION
Until recently, the only class of plasma membrane
transporters which are known to mediate the uptake of
monocarboxylates such as lactate, pyruvate, and short-chain
fatty acids in mammalian cells was the H
+-coupled mono-
carboxylate transporters (MCTs) (1,2). MCTs belong to the
solute carrier gene family SLC16 and mediate the co-
transport of monocarboxylic substrates with H
+ with a H
+:
substrate stoichiometry of 1:1. Consequently, the transport
process via MCTs is electroneutral. Recently, a second class
of monocarboxylate transporters has been identiﬁed. There
are two members in this class, and both of them mediate the
cellular uptake of monocarboxylic substrates in a Na
+-
coupled manner. This novel class of monocarboxylate
transporters, known as sodium-coupled MCTs (SMCTs),
plays an important role in the handling of a wide variety of
endogenous monocarboxylates in various tissues. In addition,
one member of this class functions as a tumor suppressor with
therapeutic potential in cancer treatment and also as a drug
transporter with potential to modulate oral absorption and
pharmacokinetics of various monocarboxylic drugs.
MOLECULAR AND FUNCTIONAL IDENTIFICATION
OF SODIUM-COUPLED MCTS
In 2003, Li et al.( 3) identiﬁed a transporter gene which
functions as a tumor suppressor in human colon. This gene,
SLC5A8, belongs to the solute carrier gene family SLC5. The
gene is expressed in normal colon, but silenced in colon
cancer and also in a variety of colon cancer cell lines. The
silencing involves DNA methylation. Ectopic expression of
the transporter in transporter-deﬁcient colon cancer cell lines
leads to suppression of colony-forming ability of these cells,
thus establishing the tumor-suppressive function of the
transporter. Even though the studies by Li et al.( 3)
established the role of this transporter as a tumor suppressor,
the actual function of the transporter was not identiﬁed. Li et
al.( 3) called this transporter a “sodium transporter” because
it belongs to the SLC5 gene family which consists of Na
+-
coupled transporters for a variety of substrates (Table I). The
ability of SLC5A8 to transport Na
+ was demonstrated by
these investigators in X. laevis oocytes following heterologous
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mcg.edu)expression of the transporter, but the substrate that was
cotransported with Na
+ was never identiﬁed. We had cloned
the same transporter a few years earlier from a kidney cDNA
library, but were unable to establish its transport function.
The ﬁndings by Li et al.( 3) showed for the ﬁrst time that the
transporter is expressed not only in the kidney but also in the
colon and that the function of the transporter is somehow
related to tumor suppression. These new ﬁndings provided an
important clue as to the actual transport function of SLC5A8.
It has been known for several decades that ﬁber intake in the
diet reduces the risk for colon cancer and that bacterial
fermentation of ﬁber in the colonic lumen generates short-
chain fatty acids which are likely to be responsible for this
tumor-suppressive effect (4,5). These bacterial metabolites
are monocarboxylates which include acetate, propionate, and
butyrate. Among these, butyrate is an inhibitor of histone
deacetylases and is known to promote differentiation in
normal colon epithelial cells but induce apoptosis selectively
in tumor cells. Based on these ﬁndings, we hypothesized that
SLC5A8 may function as a transporter for these short-chain
fatty acids. If SLC5A8 functions as a Na
+-coupled transporter
for butyrate, it would provide a logical explanation for its
expression in normal colon where cellular uptake of butyrate
via the transporter might underlie the biologic actions of this
bacterial metabolite in colon epithelial cells. It would also
provide a molecular basis for the tumor-suppressive function
of the transporter and a rationale why the expression of the
transporter is silenced in cancer. Therefore, we tested
whether SLC5A8 could function as a transporter for
butyrate and other short-chain fatty acids. These studies led
to the discovery that SLC5A8 is indeed a transporter for
monocarboxylates and that the transport process is Na
+-
dependent and electrogenic (6). Curiously, the ability of
SLC5A8 to transport short-chain fatty acids does not explain
why the transporter is expressed at high levels in the kidney
because the concentrations of these monocarboxylates in
circulation are very low. But, lactate and pyruvate, which are
also monocarboxylates similar to short-chain fatty acids, are
present in signiﬁcant amounts in circulation and these
metabolites are efﬁciently reabsorbed in the kidney with
minimal urinary excretion. This suggests that renal tubular
cells must possess an active reabsorption mechanism for these
monocarboxylates. In fact, a Na
+-coupled transport system for
lactate and pyruvate has been identiﬁed at the functional level
in brush-border membrane of renal tubular cells (7), but the
transporter responsible for the function was not identiﬁed at
the molecular level. Therefore, we hypothesized that SLC5A8
may be the transporter that is responsible for the renal
reabsorption of lactate and pyruvate. Subsequent studies with
lactate and pyruvate as substrates showed that SLC5A8 also
functions as a Na
+-coupled transporter for these mono-
carboxylates (6,8). The transport process is electrogenic,
suggesting that more than 1 Na
+ is transported per transport
cycle with a Na
+/monocarboxylate substrate ratio of ≥2. The
afﬁnity of the transporter for these monocarboxylates is fairly
high, with Michaelis constant in the range of 200–400 μM
(Table II) .T h ei d e n t i t yo fS L C 5 A 8a saN a
+-coupled and
electrogenic transporter for short-chain fatty acids and lactate
has been conﬁrmed independently by two other groups of
investigators (9,10). Screening of additional monocarboxylates
as potential substrates for SLC5A8 has revealed that nicotinate
(a B-complex vitamin) and acetoacetate and β-hydroxybutyrate
(also known as ketone bodies) also serve as substrates for the
transporter (11,12).
While screening a mouse kidney cDNA library which
yielded SLC5A8 cDNA, we isolated a related cDNA from
the same library which codes for a transporter protein highly
homologous to SLC5A8. This transporter, known as
SLC5A12, also belongs to the same gene family as does
Table I. Members of the SLC5 Gene Family
HUGO nomenclature Common name Transport function
SLC5A1 SGLT1 Na
+/glucose or
Na
+/galactose
SLC5A2 SGLT2 Na
+/glucose
SLC5A3 SMIT1 Na
+/myoinositol
SLC5A4 SGLT3 Glucose-sensitive
Na
+-channel
SLC5A5 NIS Na
+/iodide
SLC5A6 SMVT Na
+/biotin or
Na
+/pantothenate
SLC5A7 CHT1 Na
+/Cl
−/choline
SLC5A8 SMCT1 Na
+/monocarboxylate
SLC5A9 SMT Na
+/mannose
SLC5A10 ? Unknown
SLC5A11 SMIT2 Na
+/myoinositol
SLC5A12 SMCT2 Na
+/monocarboxylate
SGLT Sodium/glucose cotransporter, SMIT sodium/myoinositol
cotransporter, NIS Na
+/iodide symporter, SMVT sodium-coupled
multivitamin transporter, CHT choline transporter, SMT sodium/
mannose cotransporter, SMCT sodium-coupled monocarboxylate
transporter, HUGO human genome organization
Table II. Afﬁnities for Various Monocarboxylates for Transport Via
Human SLC5A8
Monocarboxylate Km (μM)
Acetate 2,460±890
a
Propionate 127±14
a, 128±4
b, 162±26
c
Butyrate 72±8
b,8 1 ± 1 7
a
L-Lactate 159±24
b, 184±8
d, 235±24
a
D-Lactate 742±330
a, 1,088±68
d
Pyruvate 387±43
d
Nicotinate 230±16
e, 390±36
c
Acetoacetate 213±39
d
β-D-Hydroxybutyrate 1,442±124
d
β-L-Hydroxybutyrate 2,327±169
d
g-Hydroxybutyrate 1,620±86
f
α-Ketoisocaproate 209±27
d
Benzoate 1,100±200
e
Salicylate 1,500±100
e
5-Aminosalicylate 6,500±1,000
e
aValues are from (6).
bValues are from (9).
cValues are from (10).
dValues are from (12).
eValues are from (16).
fValues are from present study.
Values were determined using substrate-induced currents as a
measure of transport in X. laevis oocytes expression system, following
heterologous expression of human SLC5A8. Data are from (6), (9),
(10), (12), and (16).
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intestinal tract, and to a lesser extent in the brain and retina.
We have now established the transport function of SLC5A12
(13,14). It also mediates Na
+-coupled transport of mono-
carboxylates, but the transport process seems to be electro-
neutral with a Na
+:monocarboxylate stoichiometry of 1:1. The
substrate selectivity of SLC5A12 is similar to that of SLC5A8,
but SLC5A12 is a low-afﬁnity transporter while SLC5A8 is a
high-afﬁnity transporter.
EXPRESSION PATTERN OF SLC5A8 AND SLC5A12 IN
THE INTESTINAL TRACT AND KIDNEY
SLC5A8 is expressed differentially in the lumen-facing
apical membrane of colonic and intestinal epithelial cells
(15,16). This localization is appropriate to its postulated
physiologic role in the cellular uptake of short-chain fatty acids
which are generated in the colonic/intestinal lumen by bacterial
fermentation of dietary ﬁber. The expression pattern of
SLC5A12 in the intestinal tract has not been studied. In the
kidney, SLC5A8 is expressed in the apical membrane of
tubular epithelial cells and the expression is restricted princi-
pally to the straight portion of the proximal tubule (S3
segment) (14). In contrast, SLC5A12 is expressed also in the
apical membrane of tubular epithelial cells but its expression is
evident all along the proximal tubule (S1, S2, and S3 segments)
(14). This makes sense in terms of the proposed physiologic
role of these transporters in the renal reabsorption of lactate.
Plasma levels of lactate are 1–1.5 mM. Therefore, the
concentration of lactate in the tubular ﬁltrate is expected to
be in millimolar range in the initial portions of the proximal
tubule. A low-afﬁnity transporter such as SLC5A12 is appro-
priate to mediate effective reabsorption of lactate at these
concentrations. Accordingly, this transporter is expressed at
high levels in epithelial cells lining the initial portions of the
proximal tubule. As lactate reabsorption continues via
SLC5A12 along the proximal tubule, the concentration is
expected to fall as the ﬂuid moves along the tubule, and a
transporter with relatively higher afﬁnity for lactate is appro-
priate to mediate lactate reabsorption under these conditions.
SLC5A8 satisﬁes this need. Accordingly, this high-afﬁnity
transporter is expressed primarily in the late portions of the
proximal tubule. Thus, the segmental localization of these two
transporters is suitable for effective reabsorption of lactate in
the kidney. The obligatory role of these transporters in lactate
reabsorption in the kidney has recently been conﬁrmed using a
transgenic mouse model (c/ebpδ null mouse) (17). C/EBPδ is a
member of the CCAAT/enhancer binding protein (C/EBP)
family (18). c/ebpδ
−/− mice are viable, but exhibits defects in
adipocyte differentiation (19), learning and memory (20), and
mammary gland involution (21,22). We recently found that the
expression of SLC5A8 as well as SLC5A12 in the kidney is
markedly decreased in c/ebpδ
−/− mice (17). The expression of
various other transporters is not affected. The decreased
expression of SLC5A8 and SLC5A12 leads to massive
urinary excretion of lactate in these mice with concomitant
decrease in plasma levels of lactate. This mouse model also
proved to be useful to establish a functional link between
lactate reabsorption and urate reabsorption in the kidney.
In normal kidney, reabsorption of urate is mediated by
URAT1, an anion exchanger with lactate being the principal
exchangeable anion (23). Even though there is no change in
the expression levels of URAT1 and many other transporters
in c/ebpδ
−/− mice, urinary excretion of urate is increased
signiﬁcantly (17). This indicates that effective cellular
accumulation of lactate in proximal tubular cells via SLC5A8/
SLC5A12 is necessary for optimal reabsorption of urate in
normal kidney. The defective reabsorption of lactate in c/ebpδ
−/−
mouse kidneys as a consequence of decreased expression of
SLC5A8 and SLC5A12 leads to an impairment in the renal
reabsorption of urate.
EXPRESSION OF SLC5A8 AND SLC5A12
IN THE BRAIN AND RETINA AND THEIR
POTENTIAL BIOLOGIC ROLE
The ﬁndings that SLC5A8 is able to transport lactate and
ketone bodies (β-hydroxybutyrate and acetoacetate) (12)
prompted us to examine the expression of the transporter in
the brain. It is well known that increased brain activity is
associated with increased utilization of glucose, but the uptake
and metabolism of glucose is enhanced not in activated
neurons but in astrocytes. Glutamate, the major neurotrans-
mitter in the brain, links neuronal activation to astrocyte
metabolism to enhance glucose breakdown via glycolysis,
leading to generation and release of lactate from the astrocytes
(24). Activated neurons then take up lactate to replenish their
energy stores. Similarly, when glucose is not available as in
prolonged starvation or is not metabolically usable as in
untreated diabetes, neurons in the brain rely on ketone bodies
as the energy source. These ketone bodies are generated by
the liver and also by the astrocytes via β-oxidation of fatty
acids. Thus, there is a close functional relationship between
neurons and astrocytes in terms of energy metabolism.
Astrocytes provide metabolic support to activated neurons by
generating lactate and ketone bodies as the immediate energy
source for neurons. This model of neuroenergetics necessitates
expression of efﬁcient transporters in neurons for uptake of
lactate and ketone bodies. MCTs are known to play a role in
this process (25). There is a differential expression of MCT
isoforms in neurons versus astrocytes, with MCT2 principally in
neurons and MCT1 and MCT4 in astrocytes. However, MCTs
are not very effective in concentrative uptake of lactate and
ketone bodies because of their energetics (coupling with
transmembrane H
+ gradient and electroneutral nature of the
transport process). In addition, MCTs exhibit low afﬁnity for
their substrates, the values for Michaelis constant generally
being in millimolar range. Therefore, we asked if SLC5A8, a
highly concentrative transporter for lactate and ketone bodies
because of its coupling to transmembrane Na
+ gradient and the
electrogenic nature of the transport process, is expressed in
neurons. Our studies have shown that it indeed is the case (12).
The expression pattern of SLC5A8 in the brain overlaps with
that of MCT2 (a neuron-speciﬁc MCT), NeuN (a neuronal cell
body marker) and MAP2 (a neuronal axonal marker). There is
no overlap between SLC5A8 expression pattern and that of
MCT1 (an astrocyte-speciﬁc MCT) and GFAP (a glial cell
marker). These studies show that the high-afﬁnity sodium-
coupled MCT SLC5A8 is expressed speciﬁcally in neurons in
the brain, suggesting that the transporter might play an
important role in the neuronal uptake of lactate and ketone
bodies and thus in the maintenance of energy status of the
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SLC5A12 is expressed speciﬁcally in astrocytes (26). The
physiologic role of this transporter in astrocytes remains to be
established. A similar expression pattern of SLC5A8 and
S L C 5 A 1 2i sa l s os e e ni nt h er e t i n a( 26). SLC5A8 is
expressed primarily in neurons and in the retinal pigment
epithelium whereas SLC5A12 is expressed almost exclusively
in Müller cells, the glial cells of the retina. Despite the
differential expression of the isoforms of MCTs and SMCTs
in neurons versus astrocytes and the in vitro evidence for their
potential physiologic functions, the relevance of these
transporters to the maintenance of energy status of the brain
in vivo remains to be established.
SLC5A8 AS A TUMOR SUPPRESSOR IN THE COLON:
THE BUTYRATE AND HDAC CONNECTION
The studies by Li et al.( 3) have unequivocally shown that
SLC5A8 functions as a tumor suppressor in the colon, but the
molecular mechanism underlying its tumor-suppressive func-
tion was not known. We hypothesized that the ability of
SLC5A8 to mediate concentrative uptake of butyrate, an
inhibitor of histone deacetylases (HDACs), from the colonic
lumen into colon epithelial cells might underlie the tumor-
suppressive function of the transporter. To test this hypothesis,
we screened several colon cell lines for the expression of the
transporter. Unpublished data from our laboratory have shown
that non-malignant colon cell lines express the transporter
whereas malignant cell lines do not. Exposure of non-
malignant cell lines to butyrate does not induce apoptosis even
though these cell lines express the transporter, indicating that
butyrate entry into cells is not detrimental to non-malignant
cells. Exposure of malignant cells to butyrate also does not
induce apoptosis. This is predictable because of the absence of
SLC5A8 and consequently the absence of concentrative
uptake of butyrate in these cells. When SLC5A8 is expressed
ectopically in malignant cells, there is no effect as long as the
culture medium does not contain butyrate, showing that the
expression of the transporter by itself alone is insufﬁcient to
induce apoptosis. In other words, the transporter protein per se
without its transport function is not a tumor suppressor. But,
when these cells are cultured in the presence of butyrate, cells
undergo massive apoptosis (unpublished data). These studies
show that the ability of SLC5A8 to transport butyrate actively
into cells is most likely responsible for its tumor-suppressive
function in the colon. The relevance of HDAC inhibition to
apoptosis in these cells is demonstrable by examining the
acetylation status of histones. Several studies have shown that
the bacterial fermentation product butyrate causes HDAC
inhibition and suppresses cell proliferation (27–29). SLC5A8
provides a molecular link between the commensal bacteria in
the colonic lumen and the host because the transporter is
essential to mediate the beneﬁcial effects of the bacterial
metabolite butyrate in the colon (30,31).
SLC5A8 AS A TUMOR SUPPRESSOR
IN NON-COLONIC TISSUES: MECHANISM
OF TUMOR SUPPRESSION
The ﬁndings that butyrate functions as a tumor suppres-
sor via SLC5A8 are physiologically relevant only to the colon
because this tissue is exposed to butyrate from the luminal
side as a result of bacterial fermentation of dietary ﬁber. The
expression of the transporter in the lumen-facing apical
membrane of colonic epithelial cells agrees with this physio-
logic role. Interestingly, the expression of the transporter has
been shown to be silenced also in cancer of a variety of non-
colonic tissues, including thyroid, stomach, brain, breast,
pancreas, and kidney (30,31). But, unlike the colon, these
tissues are not exposed to butyrate to any signiﬁcant extent
under physiologic conditions. This raises the question as to
why cancer progression in these non-colonic tissues is
associated with silencing of the transporter. In studies by Li
et al.( 3), ectopic expression of SLC5A8 in malignant colon
cells led to growth arrest, but there was no evidence of
addition of butyrate to the culture medium in these experi-
ments. This suggested to us that there must be a SLC5A8
substrate in the culture medium which behaves similar to
butyrate as an HDAC inhibitor, and that this substrate must
also be present in circulation. This would explain the
observed induction of apoptosis in colon cancer cell lines
even in the absence of butyrate upon ectopic expression of
the transporter and also the silencing of the transporter in
cancer of non-colonic tissues. To identify this ‘mystery’
substrate of SLC5A8, we decided to generate a stable cancer
cell line expressing the transporter ectopically with the goal of
screening for the compounds in the cell culture medium for
their ability to induce apoptosis. We selected the breast
cancer cell line MCF7 for this purpose. We have shown that
breast cancer is also associated with the silencing of SLC5A8
and that MCF7 cell line, being a malignant cell, does not
express the transporter (32). Therefore, a MCF7 cell line
engineered to express SLC5A8 stably would be ideal for the
screening. Surprisingly, we were unable to generate such a
stable cell line. In the regular medium generally recommen-
ded for the culture of MCF7 cells, ectopic expression of
SLC5A8 invariably led to apoptosis, suggesting that the
culture medium used in these studies also contained the
‘mystery’ substrate. We suspected that pyruvate could be this
substrate because the culture medium for MCF7 cells is
normally supplemented with 1 mM pyruvate. SLC5A8 trans-
ports pyruvate with high afﬁnity, but there was no indication
in the literature for possible tumor-suppressive ability of this
ubiquitous metabolite. Surprisingly, when we used the culture
medium without supplementation with pyruvate, we were
able to generate stable MCF7 cell lines expressing the
transporter. These studies showed for the ﬁrst time that
pyruvate induces apoptosis in cancer cells in a SLC5A8-
dependent manner (32). Supplementation of the culture
medium with pyruvate does not do any harm to MCF7 cells
because of the lack of expression of SLC5A8; but ectopic
expression of the transporter in these cells leads to apoptosis
when cultured in the presence of pyruvate-supplemented
culture medium. It was clear now that SLC5A8-mediated
concentrative entry of pyruvate was able to induce apoptosis
in cancer cells, but the mechanism remained to be estab-
lished. Subsequent studies revealed that pyruvate is almost as
potent as butyrate in its ability to inhibit HDACs (32). The
ability of pyruvate to induce apoptosis in tumor cells via
SLC5A8 provides a rationale for the silencing of the
transporter in cancer of non-colonic tissues. These ﬁndings
are also relevant to cancer-speciﬁc cellular metabolism. It has
196 Ganapathy et al.been known for decades that tumor cells upregulate glycolysis
but silence mitochondrial oxidation (33,34). The primary end
product of cancer cell metabolism is lactate. Upregulation of
glycolysis in the absence of mitochondrial oxidation leads to an
increase in intracellular levels of pyruvate, but cancer cells
avoid accumulation of this metabolite by effectively converting
it to lactate. Interestingly, pyruvate is an inhibitor of HDACs
while lactate is not (32). Thus, accumulation of pyruvate in
cancer cells is not conducive to cell proliferation because of the
ability of this metabolite to induce apoptosis via HDAC
inhibition. In contrast, accumulation of lactate is not detrimen-
tal to cancer cells. Thus, cancer cells meet their energy demand
by enhancing glycolysis even in the absence of mitochondrial
oxidation, and prevent accumulation of pyruvate to avoid
apoptosis by effectively converting pyruvate into lactate.
RELEVANCE OF SLC5A8 TO DRUG TRANSPORT
The expression of SLC5A8 in the lumen-facing apical
membrane of epithelial cells lining the small intestine, colon,
and the renal proximal tubule indicates that the transporter
may inﬂuence oral bioavailability and renal reabsorption of
monocarboxylate drugs. Potential substrates of SLC5A8 with
pharmacological relevance include salicylates, benzoate, and
non-steroidal anti-inﬂammatory drugs. Therefore, we exam-
ined the interaction of these monocarboxylates with SLC5A8
(16,35). These studies have shown that benzoate, salicylate,
and 5-aminosalicylate are transported via SLC5A8. p-Amino-
benzoate is not recognized by the transporter. The transport
of benzoate, salicylate, and 5-aminosalicylate via SLC5A8 is
Na
+-dependent and electrogenic, involving participation of at
Fig. 1. Transport of γ-Hydroxybutyrate Via Human SLC5A8 in a Mammalian Cell Expression System.
Human SLC5A8 Was Expressed Heterologously in Human Retinal Pigment Epithelial Cell Lines HRPE by
cDNA Transfection. Cells Transfected with pSPORT1 Vector Served as the Control. a Uptake of [
3H]-γ-
Hydroxybutyrate (25 nM) Was Measured in These Cells for 15 min in the Presence (NaCl Buffer) or
Absence (N-methyl-D-glucamine Chloride Buffer) of Na
+. b Uptake of [
3H]-γ-Hydroxybutyrate (25 nM)
Was Measured in a NaCl Buffer in Vector-transfected Cells and SLC5A8 cDNA-transfected Cells in the
Presence or Absence of Unlabeled Monocarboxylate Substrates (5 mM) of the Transporter
Fig. 2. Transport of γ-Hydroxybutyrate Via Human SLC5A8 in the X. laevis Oocyte Expression System.
Human SLC5A8 Was Expressed Heterologously in X. laevis Oocytes by cRNA Injection. Water-injected
Oocytes Served as the Control. Transport of γ-Hydroxybutryate via SLC5A8 was Monitored Electrophys-
iologically using the Two-microelectrode Voltage-clamp Technique, with Membrane Potential Clamped at
−50 mV. γ-Hydroxybutyrate (GHB) Induced Inward Currents in SLC5A8-expressing Oocytes. In Contrast,
There Were No Currents in Water-injected Oocytes Under Similar Conditions. a Saturation Kinetics of
GHB-induced Currents. b Na
+-activation Kinetics of GHB-induced Currents. Since the Expression Levels
Varied from Oocyte to Oocyte, the Maximal Current Induced in Each Oocyte Was Taken as 1, and the
Currents Induced in the Same Oocyte at Different Experimental Conditions Were Expressed as a Fraction
of this Maximal Current. The Michaelis Constant Was Calculated by Fitting the Experimental Data from
Saturation Kinetics to Michaelis–Menten Equation Describing a Single Saturable System. The Hill
Coefﬁcient Was Calculated by Fitting the Experimental Data from Na
+-activation Kinetics to Hill Equation
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+ in the transport process. The Michaelis constant
for these drugs is in the range of 1–7 mM. In contrast to these
drugs, non-steroidal anti-inﬂammatory drugs such as
ibuprofen, ketoprofen, and fenoprofen interact with the
transporter but do not serve as transportable substrates
(35). Ibuprofen is able to block the transport function of
SLC5A8 by competing with transportable substrates such as
lactate, nicotinate, and short-chain fatty acids, but is not
transported. This is evident from the ability of ibuprofen
to block the SLC5A8-mediated currents induced by
transportable substrates and from the lack of transporter-
mediated currents in the presence of ibuprofen itself. Thus,
ibuprofen functions as a blocker of SLC5A8 transport
function. These ﬁndings have pharmacologic and therapeutic
signiﬁcance. 5-Aminosalicylate is a drug used in the treatment
of ulcerative colitis; therefore the intended target site for this
drug is the colon. Preparations of this drug are designed
either by speciﬁc formulation or in the form of prodrug such
that 5-aminosalicylate is released primarily in the colonic
lumen. Since the molecular target for this drug
(cyclooxygenases) is located in the cytoplasm, the drug has
to enter the colonic epithelial cells to elicit its pharmacologic
effect. The expression of SLC5A8 in the apical membrane of
these cells suggests that the transporter may be involved in
facilitating the cellular entry of this drug. The ﬁndings that
certain drugs such as ibuprofen function as blockers of this
transporter raise the possibility for drug–drug interaction at
the level of cellular uptake and oral bioavailability. A similar
phenomenon is expected to occur in the kidney in terms of
reabsorption of monocarboxylate drugs, potentially
inﬂuencing their pharmacokinetics.
Since butyrate and β-hydroxybutyrate are transportable
substrates for SLC5A8, we were curious to ﬁnd out if g-
hydroxybutyrate serves as a transportable substrate for this
transporter. g-Hydroxybutyrate is an endogenous neuromo-
dulator with signiﬁcant psychotropic effects. It is also a drug
of abuse. Our studies have shown that g-hydroxybutyrate is
transported via SLC5A8 in a Na
+-dependent manner
(Fig. 1a) and that this transport is inhibited competitively by
other substrates of the transporter (Fig. 1b). We could also
demonstrate SLC5A8-mediated transport of this drug by
monitoring inward currents induced in X. laevis oocytes
following heterologous expression of the transporter. The
currents induced by g-hydroxybutyrate are saturable with a
Michaelis constant of ∼2 mM (Fig. 2a). Analysis of Na
+-
activation kinetics of the transport process showed a
sigmoidal relationship between drug-induced currents and
Na
+ concentration with a Hill coefﬁcient of 2 (Fig. 2b). These
data show that SLC5A8 offers a Na
+-coupled electrogenic
transport system for g-hydroxybutyrate, suggesting that the
transporter may play a role in the oral bioavailability and
renal reabsorption of this drug. Table II summarizes the
Michaelis constants (Km) for various monocarboxylates for
transport via human SLC5A8.
SINGLE NUCLEOTIDE POLYMORPHISMS IN SLC5A8
AND THEIR INFLUENCE ON TRANSPORT
FUNCTION
A recent search of GenBank database indicates the
existence of several single nucleotide polymorphisms in the
gene coding for SLC5A8. While most of these SNPs are
either located in introns or result in synonymous codons with
no change in amino acid sequence, there are a few SNPs
which result in amino acid substitutions. Many of these
substitutions are conservative and therefore are unlikely to
produce dramatic effects on transport function. One SNP,
however, causes substitution of Val for Phe at position 251,
which may exert signiﬁcant inﬂuence on transport function
because of the differences in the chemical structure (aliphatic
versus aromatic) and bulkiness of the amino acids involved in
the substitution. Therefore, we examined the transport
function of the V251 variant and compared it with the
transport function of the wild type transporter (F251). The
V251 variant had signiﬁcantly less transport activity com-
pared to the wild type transporter (unpublished data). These
data may have biologic relevance because of the tumor-
suppressive function of the transporter. The SNP causing the
substitution of Val for Phe may have signiﬁcantly less tumor-
suppressive effect. These ﬁndings may also have pharmaco-
logic and therapeutic relevance because of the potential
participation of the transporter in intestinal/colonic absorption
and renal reabsorption of a variety of monocarboxylate drugs.
CONCLUSIONS
There are two sodium-coupled MCTs in mammalian
cells: SLC5A8 and SLC5A12. SLC5A8 is a Na
+-coupled,
electrogenic, high-afﬁnity transporter for short-chain fatty
acids, lactate, pyruvate, nicotinate, and ketone bodies. It is
e x p r e s s e di nt h ea p i c a lm e m b rane of intestinal/colonic
epithelial cells and renal proximal tubular cells, and in
neurons in the brain and retina. It plays an essential role in
the absorption of short-chain fatty acids and the B-complex
vitamin nicotinate in the intestine and colon, in the
reabsorption of lactate and other monocarboxylate
substrates in the kidney, and in the active uptake of lactate
and ketone bodies in neurons. This transporter also functions
as a tumor suppressor. The ability of SLC5A8 to mediate
concentrative accumulation of the histone deacetylase
inhibitors butyrate and pyruvate underlies the tumor-
suppressive function of this transporter in colonic and non-
colonic tissues. SLC5A8 is also a Na
+-coupled, electrogenic
transporter for various monocarboxylate drugs such as
benzoate, salicylates, and g-hydroxybutyrate. SLC5A12 is
also a Na
+-coupled transporter for monocarboxylates, but its
substrate afﬁnity is much lower than that of SLC5A8, and its
transport function is most likely electroneutral. Due to its low
afﬁnity, this transporter is most probably responsible for the
bulk of lactate absorption in the kidney. It is expressed in the
small intestine but not in the colon. In the brain and retina,
SLC5A12 is expressed exclusively in astrocytes and glia.
Little is known on the role of this transporter in drug
transport.
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